Progress in cardiovascular diseases最新文献

英文中文

Cover 2 (Masthead) 封二（报头）

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/S0033-0620(25)00154-9

引用次数: 0

Lipoprotein(a) in pregnancy: A systematic review and meta-analysis 妊娠期脂蛋白(a)：系统回顾和荟萃分析。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.07.012

Somayeh Makvandi , Leila Karimi , Mona Larki , Elham Manouchehri , Fatemeh Goudarzi , Salim S. Virani , Amirhossein Sahebkar

Introduction

Pregnancy induces significant metabolic changes, including altered lipid profiles, yet the role of lipoprotein(a) [Lp(a)] remains unclear. While Lp(a) levels rise during pregnancy and may be linked to complications like pre-eclampsia and gestational diabetes, existing studies show inconsistent findings. This meta-analysis aims to investigate Lp(a) levels in normal and high-risk pregnancy and its associated outcomes.

Methods

This meta-analysis followed PRISMA guidelines, systematically searching PubMed, Scopus, Web of Science, and Embase for studies comparing Lp(a) levels in normal pregnant vs. non-pregnant women, or high-risk vs. normal pregnancies. Data extraction, quality assessment, and statistical analysis were performed independently by two reviewers. Heterogeneity was assessed using I² statistics, with sensitivity analyses and GRADE evaluating evidence certainty.

Results

Forty-one studies were included (31 meta-analyzed), predominantly small cross-sectional studies. Compared with non-pregnant women, Lp(a) levels were modestly higher in healthy pregnancy (MD = 5.02 mg/dL, p = 0.01; very low-certainty evidence – GRADE). In women with pre-eclampsia, Lp(a) levels were significantly elevated compared to normotensive pregnancies (MD = 11.92 mg/dL, 95 % CI: 7.68 to 16.16, p < 0.00001; very low-certainty evidence – GRADE). Subgroup analyses demonstrated that this association was consistent across different assay methods and was also observed in both early-onset (≤34 weeks; MD = 12.91 mg/dL) and late-onset (>34 weeks; MD = 10.60 mg/dL) pre-eclampsia. No significant difference was observed in women with gestational diabetes (MD = −8.85 mg/dL, p = 0.39; very low-certainty– GRADE).

Conclusion

This meta-analysis found higher Lp(a) levels in pregnancy, especially in pre-eclampsia, but not in gestational diabetes. While these findings suggest a possible link between Lp(a) and hypertensive pregnancy complications, further studies are needed to confirm clinical relevance and establish predictive utility.

妊娠引起显著的代谢变化，包括脂质谱的改变，但脂蛋白(a) [Lp(a)]的作用仍不清楚。虽然Lp(a)水平在怀孕期间上升，可能与先兆子痫和妊娠糖尿病等并发症有关，但现有的研究结果并不一致。本荟萃分析旨在探讨正常妊娠和高危妊娠的Lp(a)水平及其相关结局。方法：本荟萃分析遵循PRISMA指南，系统检索PubMed、Scopus、Web of Science和Embase，比较正常孕妇与非孕妇、高危孕妇与正常孕妇Lp(a)水平的研究。数据提取、质量评估和统计分析由两名审稿人独立完成。采用I2统计量评估异质性，采用敏感性分析和GRADE评估证据确定性。结果：纳入41项研究（31项荟萃分析），主要是小型横断面研究。与未怀孕妇女相比，健康妊娠妇女Lp(a)水平略高(MD = 5.02 mg/dL, p = 0.01；极低确定性证据（GRADE）。在子痫前期妇女中，Lp(a)水平与正常妊娠相比显著升高(MD = 11.92 mg/dL, 95 % CI: 7.68 ~ 16.16， p 34 周；MD =  10.60 mg / dL)先兆子痫。妊娠期糖尿病患者无显著差异(MD = -8.85 mg/dL, p = 0.39；非常低确定性- GRADE)。结论：本荟萃分析发现妊娠期Lp(a)水平升高，尤其是在子痫前期，但在妊娠糖尿病中没有。虽然这些发现表明Lp(a)与高血压妊娠并发症之间可能存在联系，但需要进一步的研究来证实其临床相关性并建立预测效用。

{"title":"Lipoprotein(a) in pregnancy: A systematic review and meta-analysis","authors":"Somayeh Makvandi , Leila Karimi , Mona Larki , Elham Manouchehri , Fatemeh Goudarzi , Salim S. Virani , Amirhossein Sahebkar","doi":"10.1016/j.pcad.2025.07.012","DOIUrl":"10.1016/j.pcad.2025.07.012","url":null,"abstract":"<div><h3>Introduction</h3><div>Pregnancy induces significant metabolic changes, including altered lipid profiles, yet the role of lipoprotein(a) [Lp(a)] remains unclear. While Lp(a) levels rise during pregnancy and may be linked to complications like pre-eclampsia and gestational diabetes, existing studies show inconsistent findings. This meta-analysis aims to investigate Lp(a) levels in normal and high-risk pregnancy and its associated outcomes.</div></div><div><h3>Methods</h3><div>This meta-analysis followed PRISMA guidelines, systematically searching PubMed, Scopus, Web of Science, and Embase for studies comparing Lp(a) levels in normal pregnant vs. non-pregnant women, or high-risk vs. normal pregnancies. Data extraction, quality assessment, and statistical analysis were performed independently by two reviewers. Heterogeneity was assessed using I<sup>2</sup> statistics, with sensitivity analyses and GRADE evaluating evidence certainty.</div></div><div><h3>Results</h3><div>Forty-one studies were included (31 meta-analyzed), predominantly small cross-sectional studies. Compared with non-pregnant women, Lp(a) levels were modestly higher in healthy pregnancy (MD = 5.02 mg/dL, <em>p</em> = 0.01; very low-certainty evidence – GRADE). In women with pre-eclampsia, Lp(a) levels were significantly elevated compared to normotensive pregnancies (MD = 11.92 mg/dL, 95 % CI: 7.68 to 16.16, <em>p</em> < 0.00001; very low-certainty evidence – GRADE). Subgroup analyses demonstrated that this association was consistent across different assay methods and was also observed in both early-onset (≤34 weeks; MD = 12.91 mg/dL) and late-onset (>34 weeks; MD = 10.60 mg/dL) pre-eclampsia. No significant difference was observed in women with gestational diabetes (MD = −8.85 mg/dL, <em>p</em> = 0.39; very low-certainty– GRADE).</div></div><div><h3>Conclusion</h3><div>This meta-analysis found higher Lp(a) levels in pregnancy, especially in pre-eclampsia, but not in gestational diabetes. While these findings suggest a possible link between Lp(a) and hypertensive pregnancy complications, further studies are needed to confirm clinical relevance and establish predictive utility.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 161-179"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From prediction to precision: Artificial intelligence and emerging technologies in cardiopulmonary resuscitation 从预测到精确：人工智能和心肺复苏中的新兴技术。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.09.004

Rahul Chikatimalla , Yash Vardhan Trivedi , Himaja Dutt Chigurupati , Muhammad Shaheer Bin Faheem , Muhammed Abdullah Naveed , Yasar Sattar , Jamal S. Rana , Sivaram Neppala

Background

Cardiopulmonary resuscitation (CPR) is a vital intervention for managing cardiac arrest; however, enhancing survival rates remains a significant challenge. Recent advancements highlight the importance of integrating artificial intelligence (AI) to overcome existing limitations in prediction, intervention, and post-resuscitation care.

Methods

A thorough review of contemporary literature regarding AI applications in CPR was undertaken, explicitly examining its role in the early prediction of cardiac arrest, optimization of CPR quality, and enhancement of post-arrest outcomes. The analysis incorporated data from machine learning models, biosignal-responsive robotics, and advanced monitoring systems to showcase advancements and identify future challenges.

Results

Innovations driven by AI have significantly transformed CPR practices across multiple areas. Predictive algorithms leveraging electronic health records and continuous electrocardiogram (ECG) monitoring facilitate the early identification of at-risk patients. Additionally, AI-enhanced feedback systems improve the accuracy of chest compressions and minimize variability in manual execution. Integrating AI with automated external defibrillators (AEDs) and real-time ECG analysis increases defibrillation precision and reduces interruptions during CPR. Emerging technologies, including wearable devices, immersive training simulators, and drone-delivered defibrillators, show considerable potential in addressing response time disparities during out-of-hospital cardiac arrests. Nevertheless, ethical considerations, particularly regarding data privacy and equitable access, pose significant challenges.

Conclusions

Integrating AI into CPR practices can enhance prediction accuracy, procedural effectiveness, and survival rates. Addressing the ethical, legal, and technological barriers to successful implementation in clinical settings is crucial.

背景：心肺复苏（CPR）是处理心脏骤停的重要干预措施；然而，提高生存率仍然是一个重大挑战。最近的进展强调了整合人工智能（AI）对于克服预测、干预和复苏后护理方面的现有局限性的重要性。方法：对人工智能在心肺复苏术中的应用的当代文献进行了全面的回顾，明确地研究了人工智能在心脏骤停早期预测、优化心肺复苏术质量和增强心脏骤停后结果中的作用。分析结合了来自机器学习模型、生物信号响应机器人和先进监测系统的数据，以展示进步并确定未来的挑战。结果：人工智能驱动的创新显著改变了多个领域的心肺复苏术实践。利用电子健康记录和连续心电图（ECG）监测的预测算法有助于早期识别高危患者。此外，人工智能增强的反馈系统提高了胸外按压的准确性，并最大限度地减少了手动操作的可变性。将人工智能与自动体外除颤器（aed）和实时ECG分析相结合，可以提高除颤精度，减少心肺复苏术期间的中断。新兴技术，包括可穿戴设备、沉浸式训练模拟器和无人机提供的除颤器，在解决院外心脏骤停期间的反应时间差异方面显示出相当大的潜力。然而，伦理方面的考虑，特别是关于数据隐私和公平获取的考虑，构成了重大挑战。结论：将人工智能整合到心肺复苏术实践中可以提高预测准确性、程序有效性和生存率。解决在临床环境中成功实施的伦理、法律和技术障碍至关重要。

{"title":"From prediction to precision: Artificial intelligence and emerging technologies in cardiopulmonary resuscitation","authors":"Rahul Chikatimalla , Yash Vardhan Trivedi , Himaja Dutt Chigurupati , Muhammad Shaheer Bin Faheem , Muhammed Abdullah Naveed , Yasar Sattar , Jamal S. Rana , Sivaram Neppala","doi":"10.1016/j.pcad.2025.09.004","DOIUrl":"10.1016/j.pcad.2025.09.004","url":null,"abstract":"<div><h3>Background</h3><div>Cardiopulmonary resuscitation (CPR) is a vital intervention for managing cardiac arrest; however, enhancing survival rates remains a significant challenge. Recent advancements highlight the importance of integrating artificial intelligence (AI) to overcome existing limitations in prediction, intervention, and post-resuscitation care.</div></div><div><h3>Methods</h3><div>A thorough review of contemporary literature regarding AI applications in CPR was undertaken, explicitly examining its role in the early prediction of cardiac arrest, optimization of CPR quality, and enhancement of post-arrest outcomes. The analysis incorporated data from machine learning models, biosignal-responsive robotics, and advanced monitoring systems to showcase advancements and identify future challenges.</div></div><div><h3>Results</h3><div>Innovations driven by AI have significantly transformed CPR practices across multiple areas. Predictive algorithms leveraging electronic health records and continuous electrocardiogram (ECG) monitoring facilitate the early identification of at-risk patients. Additionally, AI-enhanced feedback systems improve the accuracy of chest compressions and minimize variability in manual execution. Integrating AI with automated external defibrillators (AEDs) and real-time ECG analysis increases defibrillation precision and reduces interruptions during CPR. Emerging technologies, including wearable devices, immersive training simulators, and drone-delivered defibrillators, show considerable potential in addressing response time disparities during out-of-hospital cardiac arrests. Nevertheless, ethical considerations, particularly regarding data privacy and equitable access, pose significant challenges.</div></div><div><h3>Conclusions</h3><div>Integrating AI into CPR practices can enhance prediction accuracy, procedural effectiveness, and survival rates. Addressing the ethical, legal, and technological barriers to successful implementation in clinical settings is crucial.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 97-107"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to facilitate smoking cessation 如何促进戒烟。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.07.007

Furio Colivicchi , Stefania Angela Di Fusco , Vered Gil Ad , Silvia Castelletti , Luigi Pollarolo , Maria Laura Canale , Simona Giubilato , Roberta Rossini , Stefano Oliva , Andrea Tedeschi , Alessandra Greco , Myriam Rita Intravaia , Francesco Antonio Veneziano , Piero Clavario , Claudio Bilato , Marco Corda , Giovanna Geraci , Attilio Iacovoni , Alessandro Navazio , Federico Nardi , Fabrizio Oliva

Despite a decline in global smoking prevalence over recent decades, cigarette smoking remains one of the main modifiable risk factors for cardiovascular disease. The cardiovascular benefits of smoking cessation are well established; however, quitting smoking remains a major challenge. In this review, we aim to highlight useful tools to support smokers in their cessation journey. These include brief counseling, cognitive and behavioral interventions, and pharmacological therapies (e.g. nicotine replacement therapy, bupropion, varenicline). We also discuss evidence regarding eHealth-based interventions and the potential impact of e-cigarettes on smoking cessation. Finally, we focus on the role of public health interventions in promoting smoking cessation.

尽管近几十年来全球吸烟率有所下降，但吸烟仍然是心血管疾病的主要可改变危险因素之一。戒烟对心血管的益处是众所周知的；然而，戒烟仍然是一个重大挑战。在这篇综述中，我们的目的是强调有用的工具，以支持吸烟者戒烟的旅程。这些措施包括简短咨询、认知和行为干预以及药物治疗（如尼古丁替代疗法、安非他酮、伐尼克兰）。我们还讨论了有关基于电子健康的干预措施和电子烟对戒烟的潜在影响的证据。最后，我们重点讨论公共卫生干预措施在促进戒烟方面的作用。

{"title":"How to facilitate smoking cessation","authors":"Furio Colivicchi , Stefania Angela Di Fusco , Vered Gil Ad , Silvia Castelletti , Luigi Pollarolo , Maria Laura Canale , Simona Giubilato , Roberta Rossini , Stefano Oliva , Andrea Tedeschi , Alessandra Greco , Myriam Rita Intravaia , Francesco Antonio Veneziano , Piero Clavario , Claudio Bilato , Marco Corda , Giovanna Geraci , Attilio Iacovoni , Alessandro Navazio , Federico Nardi , Fabrizio Oliva","doi":"10.1016/j.pcad.2025.07.007","DOIUrl":"10.1016/j.pcad.2025.07.007","url":null,"abstract":"<div><div>Despite a decline in global smoking prevalence over recent decades, cigarette smoking remains one of the main modifiable risk factors for cardiovascular disease. The cardiovascular benefits of smoking cessation are well established; however, quitting smoking remains a major challenge. In this review, we aim to highlight useful tools to support smokers in their cessation journey. These include brief counseling, cognitive and behavioral interventions, and pharmacological therapies (e.g. nicotine replacement therapy, bupropion, varenicline). We also discuss evidence regarding eHealth-based interventions and the potential impact of e-cigarettes on smoking cessation. Finally, we focus on the role of public health interventions in promoting smoking cessation.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 32-42"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study 一项具有全国代表性的研究：在美国的超越- cvot的普遍性。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.08.009

Rahul Aggarwal , Stephen J. Nicholls , David D'Alessio , Deepak L. Bhatt

引用次数: 0

Contemporary management of ischemic cardiomyopathy: The synergy of medical, revascularization, and device therapies 缺血性心肌病的当代管理：医学、血运重建和器械治疗的协同作用。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.04.001

Ameesh Isath, Julio A. Panza

Ischemic heart disease (IHD) is the leading global cause of death, affecting millions and leading to significant morbidity and mortality. Ischemic cardiomyopathy (ICM), a manifestation of IHD, results in severe left ventricular dysfunction due to coronary artery disease and poses a significant challenge due to the complex pathophysiology, variable clinical presentation, and overall poor prognosis. Recent advances in medical therapy, device interventions, and revascularization techniques offer newfound hope in improving ICM patient outcomes. This article reviews the state-of-the-art management approaches for ICM, emphasizing the importance of personalized treatment plans that integrate the various contemporary therapies to address the multiple mechanisms of disease development and progression. A meticulously tailored treatment approach for each individual patient offers the hope of prolonged survival through the synergy of therapies designed to address the different and complex mechanisms that contribute to their disease process.

缺血性心脏病（IHD）是全球主要的死亡原因，影响数百万人，并导致严重的发病率和死亡率。缺血性心肌病（ICM）是IHD的一种表现形式，由于冠状动脉病变导致严重的左心室功能障碍，其病理生理复杂，临床表现多变，整体预后较差，给IHD的治疗带来了重大挑战。医学治疗、器械干预和血运重建技术的最新进展为改善ICM患者的预后提供了新的希望。本文回顾了最先进的ICM管理方法，强调了个性化治疗计划的重要性，该计划整合了各种当代疗法，以解决疾病发展和进展的多种机制。为每位患者精心定制的治疗方法，通过针对导致其疾病过程的不同和复杂机制的治疗协同作用，为延长生存提供了希望。

引用次数: 0

RSV in cardiovascular care: When the lungs speak to the heart 呼吸道合胞病毒在心血管护理中的作用：当肺部与心脏对话时。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.07.003

Paul Loubet , François Roubille

引用次数: 0

APOC3 inhibition: The strongest case yet for triglyceride targeting APOC3抑制：甘油三酯靶向的最强案例。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.09.006

Michael D. Shapiro , Leandro Slipczuk

引用次数: 0

List of recent issues 近期刊物一览表

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/S0033-0620(25)00156-2

引用次数: 0

The colchicine–sodium-glucose cotransporter two inhibitors conundrum: Promise, pitfalls, and next steps 秋水仙碱-钠-葡萄糖共转运蛋白两种抑制剂难题：前景、陷阱和下一步。

IF 7.6 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Progress in cardiovascular diseases

Pub Date : 2025-09-01 DOI: 10.1016/j.pcad.2025.10.001

Ali Bin Abdul Jabbar , Asma Ahmed , Salim S. Virani

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Progress in cardiovascular diseases

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀